Edward Cowen, M.D., leads the NIH Dermatology Consultation Service and oversees the Branch continuing medical education and resident education programs.
The Dermatology Branch conducts both clinical and basic research studying the etiology, diagnosis, and treatment of inflammatory and malignant diseases involving the skin and the host's response to these diseases.
Dr. Nagao’s research focuses on cellular and molecular mechanisms that regulate immunological and structural homeostasis in the skin.
What is scleroderma? Scleroderma is an autoimmune connective tissue and rheumatic disease that causes inflammation in the skin and other areas of the body. This inflammation leads to patches of tight, hard skin. Scleroderma involves many systems in your body. A connective tissue disease is one that affects tissues such as skin, tendons, and cartilage. There are two major types of scleroderma: Localized scleroderma only affects the skin and the structures directly under the skin. Systemic scleroderma, also called systemic sclerosis, affects many systems in the body. This is the more serious type of scleroderma and can damage your blood
What is hidradenitis suppurativa? Hidradenitis suppurativa is a skin disease that causes pimple-like bumps or boils on and under the skin. The disease is chronic (long lasting) and can be painful. HS does not spread from one person to another. HS starts in the hair follicle in the skin and happens where areas of skin may touch or rub together. Poor personal hygiene habits, such as not bathing or shampooing your hair, do not cause HS. In most cases, the cause of the disease is unknown.
Discussing Bone, Muscle, Skin, & Autoimmune Diseases: Info for American Indians, Alaska Natives - audio
A conversation between Dr. David R. Wilson, director of the NIH Tribal Health Research Office, and Dr. Lindsey A. Criswell, director of NIAMS, about information and resources for American Indians and Alaska Natives related to bone, muscle, skin, and autoimmune diseases.
The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.